MedPath

Intranasal Midazolam in Children as a Pre-Operative Sedative - Part 2

Phase 4
Completed
Conditions
Sedation
Interventions
Drug: saline placebo
Registration Number
NCT02356705
Lead Sponsor
Jennifer Victory, RN, CCRC
Brief Summary

Midazolam is often given before surgery to sedate a patient before anesthesia is given. Children are often given a small dose either by mouth or squirted into the nose. Children will often spit out the oral midazolam, making it difficult to know how much medicine, if any, they have received. Giving midazolam into the nose is more reliable, but children may complain of pain, stinging, and may become upset due to the discomfort. Nosebleeds may also occur when midazolam is squirted alone into the nose. The purpose of this study is to see if adding a numbing medicine, xylocaine, to the nasal midazolam makes giving the midazolam easier and more comfortable without affecting how the midazolam works as a sedative. This is follow up to the pilot study, Project # 994. This will expand the previous study, with additional participants and revised xylocaine concentration

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
42
Inclusion Criteria
  1. Children aged 18 months-7 years, scheduled for a minor Ear/Nose/Throat surgical procedure requiring mask anesthesia
  2. American Society of Anesthesiologists (ASA) Class 1 or 2
  3. Parent willing and able to provide written informed consent
  4. Parent willing and able to complete the Observed Behavioral Distress (OBD) Visual Assessment Scale (VAS)
Exclusion Criteria
  1. ASA Class 3 or greater
  2. History of allergy to midazolam or xylocaine
  3. Presence of acute respiratory infection at time of surgery
  4. Parent unwilling or unable to provide informed consent
  5. Parent unwilling or unable to complete the OBD VAS

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Saline Placebosaline placeboControl patients will receive intranasal saline
Nasal Midazolam OnlyMidazolamPatients will receive 0.2 mg/kg of intranasal midazolam
Midazolam Plus XylocaineMidazolamPatients will receive 0.2 mg/kg intranasal midazolam plus xylocaine 4% in a dose based on 50% of the volume of the midazolam.
Midazolam Plus XylocainexylocainePatients will receive 0.2 mg/kg intranasal midazolam plus xylocaine 4% in a dose based on 50% of the volume of the midazolam.
Primary Outcome Measures
NameTimeMethod
Pediatric Pre-Induction Anesthesia Scale at Time of Mask Placement25 minutes

Pediatric Response to Mask Placement Scale - scaled scored by the anesthesiologist or certified nurse anesthetist (CRNA) at the time of mask placement

* 1. Agitated: Previous criteria and/or refuses mask. (worst score)

* 2. Alert: Previous criteria and/or initially refuses mask, but accept after persuasion.

* 3. Calm: Previous criteria and accepts mask.

* 4. Drowsy: Previous criteria and accepts mask.

* 5. Asleep: Previous criteria and accepts mask. (best score)

Secondary Outcome Measures
NameTimeMethod
Pediatric Pre-Induction Anesthesia Scale at Arrival to Operating Room20 minutes

Pediatric Pre-Induction Anesthesia Scale - scored by the anesthesiologist or the CRNA upon arrival to the operating room, prior to induction of anesthesia

* 1. Agitated: Patient clinging to parents and/or crying (worst score)

* 2. Alert: Patient is aware but not clinging to parent, may whimper but not cry.

* 3. Calm: Sitting or lying comfortably with spontaneous eye opening.

* 4. Drowsy: Sitting or lying comfortably with eyes closed, but responding to minor stimulation.

* 5. Asleep: Eyes closed, arousable but does not respond to minor stimulation. (best score)

Trial Locations

Locations (1)

Bassett Healthcare Network

🇺🇸

Cooperstown, New York, United States

© Copyright 2025. All Rights Reserved by MedPath